Publications by authors named "Agnes Portron"

Claim this Profile
C
Clinical pharmacology of emicizumab for the treatment of hemophilia A.
Koichiro Yoneyama, Christophe Schmitt, Agnès Portron, Anna Kiialainen, Naoki Kotani

Expert Rev Clin Pharmacol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a population pharmacokinetic model to characterize the pharmacokinetics of intrathecally administered tominersen in cerebrospinal fluid and plasma.
Yumi Yamamoto, Patricia Sanwald Ducray, Marcus Björnsson, Kevin Smart, Paul Grimsey, Agnes Portron

CPT Pharmacometrics Syst Pharmacol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Study to Assess the Effect of Speed of Injection on Pain, Tolerability, and Pharmacokinetics After High-volume Subcutaneous Administration of Gantenerumab in Healthy Volunteers.
Agnès Portron, Paul Jordan, Kristy Draper, Christopher Muenzer, Daniel Dickerson

Clin Ther· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Tofogliflozin (A SELECTIVE SGLT2 Inhibitor) in Patients with Type 2 Diabetes Mellitus.
Sachiya Ikeda, Yasuki Takano, Dietmar Schwab, Agnes Portron, Nahoko Kasahara-Ito

Drug Res (Stuttg)· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
Steven W Pipe, Midori Shima, Michaela Lehle, Amy Shapiro, Sammy Chebon, Agnès Portron

Lancet Haematol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 in people with type 2 diabetes mellitus.
Christophe Schmitt, Agnès Portron, Shirin Jadidi, Neena Sarkar, Richard DiMarchi

Diabetes Obes Metab· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 after single subcutaneous administration in healthy subjects.
Agnès Portron, Shirin Jadidi, Neena Sarkar, Richard DiMarchi, Christophe Schmitt

Diabetes Obes Metab· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral administration of the 11β-hydroxysteroid-dehydrogenase type 1 inhibitor RO5093151 to patients with glaucoma: an adaptive, randomised, placebo-controlled clinical study.
Dietmar Schwab, Carolina Sturm, Agnès Portron, Sabine Fuerst-Recktenwald, Dominik Hainzl

BMJ Open Ophthalmol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]tofogliflozin after oral administration and concomitant intravenous microdose administration of [13C]tofogliflozin in humans.
Dietmar Schwab, Agnes Portron, Zoe Backholer, Berthold Lausecker, Kosuke Kawashima

Clin Pharmacokinet· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis